In 2001, Martinez et al. firstly described the relationship between the TNF-α blockade and HS and observed an improvement in HS manifestations in a patient with Crohn’s disease treated with a TNF-α inhibitor (infliximab) [72]. Here, TNF is linked to Crohn disease.